News & Sentiment
$15M Investment to Launch High Tech Ice Manufacturing Facility in Oak Park - 50 New Jobs
Motor City Ice repurposes former 30,000-square-foot Forgotten Harvest building into a fully automated ice production facility serving Metro Detroit. DETROIT, Oct. 27, 2026 /PRNewswire/ -- A group of three established Metro Detroit business families has invested more than $15 million to...
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
947 articles
📰
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
Jazz Pharmaceuticals' strategy is starting to pay dividends.
📰
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
The stocks listed here yield up to 5.8%.
📰
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
The stocks listed here yield up to 5.8%.
📰
Nvidia Plays Kingmaker Again. Why the Meta Deal Is a Winning Move.
Nvidia will invest $3 billion in Meta Platforms as part of a larger partnership.
📰
Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript
RNA medicine company advances obesity and lung disease programs with $431M cash runway.
📰
IQVIA (IQV) Q3 2026 Earnings Call Transcript
Revenue hit $4.4 billion with 8% growth; net new bookings surged 15% year over year.
📰
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders.
📰
Twist Bioscience Rallies as Investors Revisit Growth Outlook Ahead of Earnings - Quiver Quantitative
Twist Bioscience Rallies as Investors Revisit Growth Outlook Ahead of Earnings Quiver Quantitative
Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/Y
ECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital...
Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/Y
ECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital...
Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/Y
ECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital...
📰
Pharming (PHAR) Q3 2026 Earnings Call Transcript
Revenue grew 21% year-over-year as RUCONEST stabilized and Joenja expanded internationally.
📰
Nautilus (NAUT) Q3 2026 Earnings Call Transcript
Cash reserves extend runway into early 2028 as proteoform assay pipeline accelerates.
📰
Novartis (NVS) Q3 2026 Earnings Call Transcript
Priority brands offset generic erosion as margin expands and pipeline advances.
📰
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance.
📰
Repligen (RGEN) Q3 2026 Earnings Call Transcript
BioLife acquisition bolsters cell therapy as chromatography and proteins surge.
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer...
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer...
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer...
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer...
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on...
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on...
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on...
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on...
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory...
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions
HCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory...
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory...
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions
HCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory...
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions
HCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions
HCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat...
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat...
📰
BBLG Earnings Illustrate Opportunity
By Brad Sorensen, CFA
NASDAQ: BBLG
READ THE FULL BBLG RESEARCH REPORT
Bone Biologics Corporation (NASDAQ: BBLG) continues to make encouraging...
📰
Danaher (DHR) Upgraded to Buy: Here's Why
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).